Ginkgo Bioworks Stock Forecast
NYSE: DNAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
DNA analyst consensus
Consensus (3 analysts)
none
Avg. price target
$7.00-46.15%
- Strong buy 0
- Buy 0
- Hold 1
- Sell 1
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 3 Wall Street analysts covering Ginkgo Bioworks (2026-10-09), 0 rate the stock a buy or strong buy, 1 rate it a hold and 2 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $7.00, with a high estimate of $9.00 and a low estimate of $5.00. The average target implies downside of 46.2% from the current price of $13.00.
The spread between the highest and lowest targets is 80.0%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for DNA.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 0 | 0% |
| Hold | 1 | 33% |
| Sell | 1 | 33% |
| Strong sell | 1 | 33% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $5.00 | -61.54% |
| Average target | $7.00 | -46.15% |
| High target | $9.00 | -30.77% |